Literature DB >> 3963979

Minoxidil, nadolol, and a diuretic. Once-a-day therapy for resistant hypertension.

S Spitalewitz, J G Porush, I W Reiser.   

Abstract

We tested a once-a-day antihypertensive regimen using minoxidil, nadolol, and a diuretic in 55 patients with resistant hypertension. Forty-seven patients had evidence of end-organ damage. Twelve had mild renal insufficiency (serum creatinine concentration, 2.5 +/- 0.3 mg/dL). In 34 patients, treatment with nadolol and a diuretic was started with minoxidil added one to four weeks later. In the remainder, minoxidil, nadolol, and a diuretic were begun simultaneously because of severe hypertension. Initial supine and standing blood pressure (BP) in the 55 patients were 186 +/- 4/111 +/- 2 and 180 +/- 4/108 +/- 2 mm Hg, respectively. After 7 +/- 1 weeks, BP was controlled in 46 patients (84%) with the supine and standing BP reduced to 140 +/- 3/80 +/- 1 and 134 +/- 3/80 +/- 1, respectively. In six patients, BP was controlled but intolerable side effects occurred, making the regimen therapeutically successful in 40 patients (73%). The BP remained controlled during a follow-up of 43 +/- 5 weeks. In 31 patients, BPs measured 24 hours after the last dose were not different from random measurements. Mean serum creatinine levels remained stable in the 12 patients with renal insufficiency.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3963979

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  2 in total

Review 1.  Preferred Fourth-Line Pharmacotherapy for Resistant Hypertension: Are We There Yet?

Authors:  Hamish Cg Prosser; Cynthia Gregory; Dagmara Hering; Graham S Hillis; Greg Perry; Johan Rosman; Carl Schultz; Mark Thomas; Gerald F Watts; Markus P Schlaich
Journal:  Curr Hypertens Rep       Date:  2017-04       Impact factor: 5.369

2.  Choosing initial antihypertensive drug therapy for the uncomplicated hypertensive patient.

Authors:  M A Moore
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 Jan-Feb       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.